Myocardial fibrosis and atrial fibrillation
https://doi.org/10.15829/1560-4071-2018-9-71-76
Abstract
Atrial fibrillation is the most prevalent arrhythmia, and tends to progress. Any structural changes in the heart may lead to its progressive remodelling with increased deposition of connective tissue and fibrosis. Predominance of collagen types I and III synthesis over its degradation leads to accumulation of fibers and to fibrosis. Increase of atrial fibrosis is usually found on autopsy and biopsy. There is relation revealed, of atrial fibrosis grade and postsurgery atrial fibrillation. The mechanisms participating in the structural remodelling and progression of atrial fibrosis are not studied well enough, but there is known role of renin-angiotensinaldosterone system, transforming growth factor, inflammation and matrix metalloproteases. As an alternative, one should consider non-invasive diagnostic methods: magnetic resonance imaging of the heart and biomarkers level measurement. Hyperactivation of the renin-angiotensin-aldosterone system facilitates structural remodelling of the heart and progression of atrial fibrosis. Hyperexpression of the transforming growth factor leads to selective atrial fibrosis, heterogeneity of excitation conduction and fibrillation onset. Matrix metalloproteases are the marker of extracellular degradation. Study of fibrosis biomarkers makes it to increase significantly the efficacy of atrial fibrillation course prediction.
About the Authors
S. V. Grigoryan
M. Geratsi Erevan State Medical University (ESMU); L.A.Oganesyan SRI of Cardiology
Armenia
Competing Interests:
Armenia
Erevan
Competing Interests:
Conflicts of Interest nothing to declare
L. G. Azarapetyan
M. Geratsi Erevan State Medical University (ESMU); L.A.Oganesyan SRI of Cardiology
Armenia
Competing Interests:
Armenia
Erevan
Competing Interests:
Conflicts of Interest nothing to declare
K. G. Adamyan
M. Geratsi Erevan State Medical University (ESMU); L.A.Oganesyan SRI of Cardiology
Armenia
Competing Interests:
Armenia
Erevan
Competing Interests:
Conflicts of Interest nothing to declare
References
1. Camm AJ, Lip GY, De Caterina R, et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-47. doi:10.1093/eurheartj/ehs253.
2. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014;129:837-47. doi:10.1161/CIRCULATIONAHA.113.005119.
3. Bassand J-P, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal. 2016; 37(38):2882-9. doi:10.1093/eurheartj/ehw233.
4. Andrade J, Khairy P, Dobrev D, et al. The clinical profileand pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ. Res. 2014;114:1453-68. doi:10.1161/CIRCRESAHA.114.303211.
5. Apostolakis S, Sullivan RM, Olshansky B, et al. Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. Int J Cardiol. 2014;170:303-8. doi:10.1016/j.ijcard.2013.11.002.
6. Golbaeva AZ, Tabina AE, Goluxova EZ. Molecular mechanisms of atrial fibrillation: in the search for an “ideal” marker. Creative cardiology. 2015;2:40-53. (In Russ.) doi:10.15275/kreatkard.2015.02.04.
7. Prabhu S, McLellan AJ, Walters TE, et al. Atrial structure and function and its implications for current and emerging treatments for atrial fibrillation. ProgCardiovasc Dis. 2015;58;15267. doi:10.1002/ejhf.645.
8. Wang W, Zhang H, Yang X. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling. J Cardiovasc Med (Hagerstown). 2013;14,4:265-69. doi:10.3892/mmr.2017.7415.
9. Dzeshka MS, Lip GY, Snezhitskiy V, et al. Cardiac fibrosis in with atrial fibrillation: mechanisms and clinical implications. J Am CollCardiol. 2015;66:943-59. doi:10.1016/j.jacc.2015.06.1313.
10. López B, González A, Ravassa S, et al. Circulating biomarkers of myocardial fibrosis. Journal of the American College of Cardiology. 2015;65(22):2449-56. doi:10.1002/ejhf.696.
11. Zile MR, Baicu CF, Ikonomidis J, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247-59. doi:10.1161/CIRCULATIONAHA.114.013215.
12. Dai Z, Aoki T, Fukumoto Y, et al. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. Journal of Cardiology. 2012;60:416-21. doi:10.1007/s00441-016-2431-9.
13. Aoki T, Fukumoto Y, Sugimura K, et al. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circulation journal. 2011;75:2605-13. doi:10.1253/circj.CJ-11-0568.
14. Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. Journal of the American College of Cardiology. 2008;51;2414-21. doi:10.1016/j.jacc.2008.03.018.
15. Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206-16. doi:10.1093/eurheartj/eht193.
16. Drapkina OM, Emelyanov AV. Atrial fibrosis is the morphological basis of atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2013;9(4):417-22. (In Russ.) doi:10.20996/1819-6446-2013-9-4-417-41.
17. Schotten U, Verheule S, Kirchhof P, et al. Pathophisiological mechanisms of atrial fibrillation–a translational appraisal. Physiol Rev. 2011;91(1):265-325. doi:10.1152/physrev.00031.2009.
18. Goette A, Juenemann G, Peters B, et al. Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovascular Research. 2002;54;390-6. doi:10.1016/S0008-6363(02)00251-1.
19. Dutta D, Calvani R, Bernabei R, et al. Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. Circulation Research. 2012;110:1125-38. doi:10.1161/CIRCRESANA.111.246108.
20. Karpenko Yu. Fibroz myocardium and arrhythmia: predicting the effect of catheter ablation. Health of Kazakhstan. 2015;6,(37):8-13. (In Russ.)
21. Treibel TA, White SK, Moon JC. Myocardial tissue characterization: histological and pathophysiological correlation. Current Cardiovascular Imaging Reports. 2014;7:9254. doi:10.1007/s12410-013-9254-9.
22. Aparina OP, Stukalova OB, Ternovaya SK. Magnetic resonance imaging with delayed contrast in atrial fibrillation: first achievements and perspectives. Medical imaging. 2017;4:47-57. (In Russ.) doi:10.24835/1607-0763-2017-4-47-57.
23. Drapkina OM. Fibrosis and activation of the renin-angiotensin-aldosterone system. Arterial Hypertension. 2012;18(5):1-10. (In Russ.)
24. Drapkina OM, Cherkunov EV. Evaluation of violations of atrial contractility and fibrosis as predictors of chronic heart failure. Rational pharmacotherapy in cardiology. 2014;10(2):231-7. (In Russ.)
25. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation J. Am. Coll. Cardiol. 2008;51:802-9. doi:10.1016/j.jacc.2007.09.064.
26. Veidal SS, Nielsen MJ, Leeming DJ, et al. Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model. BMC Res. Notes. 2012;5:686. doi:10.1186/1756-0500-5-686.
27. Fan D,Takawale A, Lee J, et al. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 2012;5:15. doi:10.1186/17551536-5-15
28. Chiang CE, Naditch-Brule L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ. Arrhythm. Electrophysiol. 2012;5:632-9. doi:10.1161/CIRCEP.112.970749.
29. Morishima M, Iwata E, Nakada C, et al. Atrial fibrillation-mediated upregulation of miR-30d regulates myocardial electrical remodeling of the G-protein-gated K(±) channel, IK.Ach. Circ. J. 2016;25,80(6):1346-55. doi:10.1253/circj.CJ-15-1276.
30. Kalogeropoulos A, Tsiodras S, Rigopoulos A, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord. 2011;28:11-77. doi:10.1186/1471-2261-11-77.
31. Ichiki T, Huntley BK, Sangaralingham SJ, et al Atrium fibrosis and inflammation: impaired atrial natriuretic peptide system in experimental heart failure. Circulation. 2014;130:A1265. doi 10.1016/j.jchf.2015.03.015.
32. Rabbat MG, Sayegh B, Stiff A, et al. Epicardial adipose tissue volume predicts extent of left atrial fibrosis in patients with atrial fibrillation. Circulation. 2014;130:A16860.
33. Venteclef N, Guglielmi V, Balse E, et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. European Heart Journal. 2013;36:795-805. doi:10.1093/eurheartj/eht099.
34. Grigoryan SV, Hazarapetyan LG, Stepanyan AA. Association between inflammation markers, recurrence of atrial fibrillation after successful cardioversion and outcome of advanced heart failure. European Heart Jоurnal Acute Cardiovascular Care. 2015;4,224:89-90.
35. Grigoryan SV, Hazarapetyan LG, Adamyan KG. Paroxysmal atrial fibrillation and inflammatory markers. European Heart Journal, Acute Cardiovascular Care. 2016;5,373:785.
36. Reil J, Hohl M, Oberhofer M, et al. Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodeling. Cardiovasc. Res. 2010;87:485-93. doi:10.1093/cvr/cvq079.
37. Nguyen BL, Fishbein MC. Histopathological substrate for chronic atrial fibrillation in humans. Heart Rhythm. 2009;6(4):454-60. doi:10.1016/j.hrthm.2009.01.010.
38. Krenning G, Zeisberg EM, Kalluri R The Origin of Fibroblasts and Mechanism of Cardiac Fibrosis, J Cell Physiol. 2010;225(3):631-7. doi:10.1002/jcp.22322.
39. Mitrofanova LB, Lebedev DS, Antonova IV, et al Comparative morphometric examination of various departments of atria with their paroxysmal and permanent fibrillation. Herald of arrhythmology. 2010;62:32-6. (In Russ.)
40. Nigmatullina RR, Mirolubov LM, Mustafin AA. Serotonergic system in the pathogenesis of the formation of pulmonary arterial hypertension in children withcongenital heart defects. Kazan Medical Journal. 2013;3:309-13. (In Russ.)
41. Vergara E. DE4MRI to determine the degree of fibrosis in the left atrial myocardial tissue of AF patients before radiofrequency ablation. J. Cardiovasc. Electrophysiol. 2011;8:54-62.
42. ElMaghawry M, Romeih S. DECAAF: Emphasizing the importance of MRI in AF ablation. Glob Cardiol Sci Pract. 2015;8. doi:10.5339/gcsp.2015.8.eCollection2015.
43. Krul SP, Berger WR, Smit NW, et al. Atrial fibrosis and conduction slowing in the left atrial appendage of patients undergoing thoracoscopic surgical pulmonary vein isolation for atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2015;8(2):288-95. doi:10.1161/CIRCEP.114.001752.
44. Goldberger JJ, Arora R, Green D, et al. Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate. Circulation. 2015;132(4):278-91. doi:10.1161/CIRCULATIONAHA.115.016795.
45. Kosiuk J, Dinov B, Kornej J, et al. Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score. Heart Rhythm. 2015 Nov;12(11):2207-12. doi:016/j.hrthm.2015.07.003.
46. Letsas KP, Efremidis M, Sgouros NP, et al Catheter ablation of persistent atrial fibrillation: The importance of substrate modification. World J. Cardiol. 2015;7(3):111-8. doi:10.4330/wjc.v7.i3.111.
47. Zimmerman SL, Philips B, Marine JE, et al The association of left atrial low-voltage regions on electroanatomic mapping with low attenuation regions on cardiac computed tomography perfusion imaging in patients with atrial fibrillation. Heart Rhythm. 2015;12(5):857-64. doi:10.1016/j.hrthm.
48. Akoum N, Wilber D, Hindricks G, et al MRI Assessment of Ablation-Induced Scarring in Atrial Fibrillation: Analysis from the DECAAF Study. J. Cardiovasc. Electrophysiol. 2015;26(5):473-80. doi:10.1111/jce.12650.
Review
For citations:
Grigoryan S.V., Azarapetyan L.G., Adamyan K.G. Myocardial fibrosis and atrial fibrillation. Russian Journal of Cardiology. 2018;(9):71-76. (In Russ.) https://doi.org/10.15829/1560-4071-2018-9-71-76
Views:
4735
Email this article 